FibroBiologics releases CYWC628 drug for Phase 1/2 trial targeting diabetic foot ulcers.

FibroBiologics has released the first batch of its CYWC628 drug product, manufactured under FDA cGMP standards, to support a Phase 1/2 clinical trial for diabetic foot ulcers (DFUs). This investigational fibroblast-based therapy aims to address DFUs, a chronic condition with limited treatment options. The trial will evaluate the drug's safety, tolerability, and preliminary efficacy, marking a key step toward potential commercial development. The company is now ready to begin patient enrollment for this trial.